Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) 101 – SOPs and Regional Regulations
RWE 101 - SOPs and Regional Regulations In the realm of quality assurance (QA), it's vital that standard operating procedures (SOPs) are crafted in a way that accurately and [...]
Real World Evidence (RWE) 101 – Standard Operating Procedures
RWE 101 - Standard Operating Procedures Standard Operating Procedures (SOPs) are critical for the operation of any business, particularly in regulated industries like pharmaceuticals where precision, safety, and compliance [...]
Real World Evidence (RWE) 101 – Publications
RWE 101 - Publications The term RWE stands for Real-World Evidence, which is evidence derived from real-world data (RWD). RWD are data relating to patient health status and/or the [...]
Real World Evidence (RWE) 101 – Archiving Specifics
RWE 101 - Archiving Specifics Proper archiving of clinical study documents is an important practice for maintaining the quality, integrity, and usability of study data, and for ensuring regulatory [...]
Real World Evidence (RWE) 101 – Archiving Generics
RWE 101 - Archiving Generics In the context of health research, both observational studies and clinical trials are crucial for understanding disease processes, patient outcomes, and the safety and [...]
Real World Evidence (RWE) 101 – Study Close-out
RWE 101 - Study Close-Out Closing out an observational study involves several key steps to ensure that all study activities are concluded properly, and data integrity is maintained. Here [...]







